Skip to main content
. 2023 Feb 1;11(2):424. doi: 10.3390/biomedicines11020424

Figure 2.

Figure 2

(A) CD34 and (B) FGF23 in different experimental groups at the end of the eighth week post treatment with VD3 against TAA-induced hepatic damage in rats (mean ± SE). Various superscripts (a, c, d, and e) are statistically different from one another (p < 0.05). CD34, cluster differentiation 34; FGF23, fibroblast growth factor 23.